Skip to content

Study · Animal study (in vivo) · 2010

2 results

Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart.

Smart N, Risebro CA, Clark JE, Ehler E, Miquerol L, Rossdeutsch A, Marber MS, Riley PR

Annals of the New York Academy of Sciences1 Apr 2010Cited by 78 (Europe PMC)

PMID20536455 (opens in a new tab)DOI10.1111/j.1749-6632.2010.05478.x (opens in a new tab)PepBankPUB-20536455
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mammalian hearts, Tbeta4 promoted new vasculature in both the intact and the injured heart.

    In plain wordsIn animal hearts, thymosin beta‑4 promoted new blood vessel growth in both healthy and injured hearts.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseNeovascularization in intact and injured heart
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that thymosin beta4 (Tbeta4) promotes new vasculature in both the intact and injured mammalian heart.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    After cardiac injury, Tbeta4 significantly augmented the limited endogenous epicardial neovascularization, increasing and stabilizing the vascular plexus via collateral vessel growth.

    In plain wordsIn injured animal hearts, thymosin beta‑4 increased the natural blood vessel repair response.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCollateral vessel growth and vascular plexus after injury
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We demonstrate that limited EPDC-derived endothelial-restricted neovascularization constitutes suboptimal "endogenous repair," following injury, which is significantly augmented by Tbeta4 to increase and stabilize the vascular plexus via collateral vessel growth.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.